It's all labeled for "research use only." Alongside reta, he lists another not-yet-for-sale drug from Novo Nordisk, called cagrilintide, or cagri, and a popular concoction: cagri-reta, blending two in-development GLP-1s from two different drugmakers
Citations Shor, R., et al, "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration," JAMA Ophthalmology, June 5, 2025, doi: 10.1001/jamaophthalmol.2025.1455 Edinoff, A.N., et al, "Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review," Health Psychology Research, Nov 3, 2022, DOI: 10.52965/001c.39580 Dalton, S.O., et al, "SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing?," CNS Drugs, 2006, DOI: 10.2165/00023210-200620020-00005 Hussain, S., et al, "Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis," Rheumatology International, Nov
Alternatives Honest bottom line: For any indication except possibly direct GI mucosal support, evidence-based alternatives outperform BPC-157 capsules simply because those alternatives have human data
Important context first: BPC-157 is not a licensed medicine in the UK, and no clinic can lawfully prescribe, sell, or post it for human use